Loss of exclusivityJuly 2039latest FDA-listed patent expiry
CompanyFennec Pharma →See this company's full patent-cliff portfolio
Drug detail
Brand name
PEDMARK
Active ingredient
SODIUM THIOSULFATE
Strength
12.5GM/100ML (125MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
Modality
Small molecule
FDA approval
September 2022
Marketing status
RX
Listed patents
Patent
Expires
Type
11291728
July 2039
product
11992530
July 2039
use U-3948
11964018
July 2039
use U-3898
11998604
July 2039
use U-3952
11617793
July 2039
product
11510984
July 2039
product
10596190
January 2038
use U-3443
Regulatory exclusivity
Code
Expires
ODE-384
September 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
PEDMARK patent cliff — loss of exclusivity July 2039 | CliffBio